logo
Plus   Neg
Share
Email

Targa Resources Q4 Loss Widens

Targa Resources Corp. (TRGP) reported that its net loss attributable to common shareholders for the fourth-quarter widened to $144.4 million from $137.0 million in the prior year.

The fourth quarter of 2019 included a pre-tax non-cash loss of $229.0 million from the impairment of property, plant and equipment from a continuing decline in natural gas production across the Barnett Shale in North Texas and Gulf of Mexico due to the sustained low commodity price environment.

The fourth quarter of 2018 included a pre-tax non-cash loss of $210.0 million from the impairment of goodwill.

Total revenues for the quarter declined to $2.47 billion from $2.60 billion in the previous year.

For 2020, Targa estimates full year Adjusted EBITDA to be between $1.625 billion and $1.750 billion, with the midpoint of the range representing an 18 percent increase over full year 2019 Adjusted EBITDA.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Novacyt S.A. said it is seeing unprecedented demand for the novel coronavirus or COVID-19 diagnostic test kit developed by Primerdesign, the company's molecular diagnostics division based in the UK. As of March 27, Primerdesign has sold and received orders for more than 17.8 million pounds of its CE-Mark COVID-19 tests. Novacyt is currently selling its COVID-19 test to more than 80 countries. The U.S. Food and Drug Administration has issued an Emergency Use Authorization to allow anti-malaria drugs hydroxychloroquine sulfate and chloroquine phosphate donated to the Strategic National Stockpile as possible treatments for coronavirus (COVID-19) patients. This is the first EUA for a drug related to the COVID-19 response. Gilead Sciences Inc. said it is transitioning to "expanded access programs" from "compassionate use" programs for its experimental anti-coronavirus drug, remdesivir. The company noted that the expanded access will allow hospitals or physicians to apply for emergency use of remdesivir for multiple severely ill patients at one time, as they struggle to deal with the COVID-19 or coronavirus pandemic.
Follow RTT
>